Plain-English translation of NCT06769126 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —an immunotherapy medication already used to treat advanced small cell lung cancer—works better when combined with one of three different additional medications during the maintenance phase of treatment. The specific second medication you would receive depends on genetic markers found in your tumor tissue, which the study team will test at the beginning. The goal is to see whether this personalized approach helps people live longer without their cancer getting worse.
Small cell lung cancer is a serious disease, and even with current treatments, many patients' cancers come back or get worse. This trial exists to see whether tailoring the maintenance treatment to each person's tumor genetics—rather than giving everyone the same treatment—can improve survival and keep the cancer under control longer.
You likely qualify if…
You likely don't qualify if…
You will first have tissue from your tumor tested to determine which treatment group you belong to. Then you will receive 4 to 6 cycles of standard induction chemotherapy combined with (each cycle lasts about 4 weeks). After that, you may receive radiation to your chest if your doctor thinks it is needed. Finally, you will move into the maintenance phase, where you will receive alone or plus one additional personalized medication every 4 weeks for as long as the treatment is working. Throughout the study, you will have regular imaging scans (CT or PET scans) and blood tests to monitor your progress.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States